Preclinical Models in Prostate Cancer: Resistance to AR Targeting Therapies in Prostate Cancer

被引:15
作者
Devlies, Wout [1 ,2 ]
Handle, Florian [3 ]
Devos, Gaetan [2 ]
Joniau, Steven [2 ]
Claessens, Frank [1 ]
机构
[1] Katholieke Univ Leuven, Lab Mol Endocrinol, B-3000 Leuven, Belgium
[2] Univ Hosp Leuven, Dept Urol, B-3000 Leuven, Belgium
[3] Med Univ Innsbruck, Dept Urol, Div Expt Urol, A-6020 Innsbruck, Austria
关键词
preclinical models; androgen receptor; prostate cancer; hormone treatment; ARSI; ARTA; treatment resistance; CARCINOMA-CELL-LINE; RECEPTOR SPLICE VARIANTS; ANDROGEN RECEPTOR; GLUCOCORTICOID-RECEPTOR; NEUROENDOCRINE TRANSDIFFERENTIATION; ENZALUTAMIDE RESISTANCE; CROSS-RESISTANCE; BONE METASTASIS; CASTRATION; ABIRATERONE;
D O I
10.3390/cancers13040915
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Simple Summary In this review, we will look into the existing methods to study treatment resistance to androgen receptor targeted therapies in prostate cancer. This will encompass both the different existing preclinical models as well as the role specific models have played in the current understanding of resistance mechanisms. Prostate cancer is an androgen-driven tumor. Different prostate cancer therapies consequently focus on blocking the androgen receptor pathway. Clinical studies reported tumor resistance mechanisms by reactivating and bypassing the androgen pathway. Preclinical models allowed the identification, confirmation, and thorough study of these pathways. This review looks into the current and future role of preclinical models to understand resistance to androgen receptor-targeted therapies. Increasing knowledge on this resistance will greatly improve insights into tumor pathophysiology and future treatment strategies in prostate cancer.
引用
收藏
页码:1 / 17
页数:16
相关论文
共 50 条
  • [11] Targeting HIF-1 for prostate cancer: a synthesis of preclinical evidence
    Zohar, Yarden
    Mabjeesh, Nicola J.
    EXPERT OPINION ON THERAPEUTIC TARGETS, 2023, 27 (08) : 715 - 731
  • [12] Targeting the androgen receptor in prostate cancer
    Culig, Zoran
    EXPERT OPINION ON PHARMACOTHERAPY, 2014, 15 (10) : 1427 - 1437
  • [13] Targeting autophagy in prostate cancer: preclinical and clinical evidence for therapeutic response
    Ashrafizadeh, Milad
    Paskeh, Mahshid Deldar Abad
    Mirzaei, Sepideh
    Gholami, Mohammad Hossein
    Zarrabi, Ali
    Hashemi, Farid
    Hushmandi, Kiavash
    Hashemi, Mehrdad
    Nabavi, Noushin
    Crea, Francesco
    Ren, Jun
    Klionsky, Daniel J.
    Kumar, Alan Prem
    Wang, Yuzhuo
    JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH, 2022, 41 (01)
  • [14] A noncanonical AR addiction drives enzalutamide resistance in prostate cancer
    He, Yundong
    Wei, Ting
    Ye, Zhenqing
    Orme, Jacob J.
    Lin, Dong
    Sheng, Haoyue
    Fazli, Ladan
    Karnes, R. Jeffrey
    Jimenez, Rafael
    Wang, Liguo
    Wang, Liewei
    Gleave, Martin E.
    Wang, Yuzhuo
    Shi, Lei
    Huang, Haojie
    NATURE COMMUNICATIONS, 2021, 12 (01)
  • [15] Androgen receptor (AR) heterogeneity in prostate cancer and therapy resistance
    Jamroze, Anmbreen
    Chatta, Gurkamal
    Tang, Dean G.
    CANCER LETTERS, 2021, 518 : 1 - 9
  • [16] Current uses and resistance mechanisms of enzalutamide in prostate cancer treatment
    Miller, Carly D.
    Likasitwatanakul, Pornlada
    Toye, Eamon
    Hwang, Justin H.
    Antonarakis, Emmanuel S.
    EXPERT REVIEW OF ANTICANCER THERAPY, 2024, 24 (11) : 1085 - 1100
  • [17] Co-targeting AR and HSP90 suppresses prostate cancer cell growth and prevents resistance mechanisms
    Centenera, Margaret M.
    Carter, Sarah L.
    Gillis, Joanna L.
    Marrocco-Tallarigo, Deborah L.
    Grose, Randall H.
    Tilley, Wayne D.
    Butler, Lisa M.
    ENDOCRINE-RELATED CANCER, 2015, 22 (05) : 805 - 818
  • [18] Drug discovery in prostate cancer mouse models
    Valkenburg, Kenneth C.
    Pienta, Kenneth J.
    EXPERT OPINION ON DRUG DISCOVERY, 2015, 10 (09) : 1011 - 1024
  • [19] Unique targeting of androgen-dependent and -independent AR signaling in prostate cancer to overcome androgen resistance
    Lim, Syer C.
    Jansson, Patric J.
    Assinder, Stephen J.
    Maleki, Sanaz
    Richardson, Des R.
    Kovacevic, Zaklina
    FASEB JOURNAL, 2020, 34 (09) : 11511 - 11528
  • [20] Mechanisms of acquired resistance to androgen receptor targeting drugs in castration-resistant prostate cancer
    Chism, David D.
    De Silva, Dinuka
    Whang, Young E.
    EXPERT REVIEW OF ANTICANCER THERAPY, 2014, 14 (11) : 1369 - 1378